CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-α therapy and toll-like receptor 3 signalling

Journal of Viral Hepatitis

Volumn 19, Issue 2, 2012, Pages 128-137

  Katsounas, A ^a,b   Trippler, M ^a   Wang, B ^a   Polis, M ^c   Lempicki, R A ^b   Kottilil, S ^c   Gerken, G ^a   Schlaak, J F ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

CCL5; fibrosis; HCV; IFN ; stellate cells

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA INTERFERON RECEPTOR 1; BIOLOGICAL MARKER; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POLYINOSINIC POLYCYTIDYLIC ACID; RANTES; RIBAVIRIN; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL THERAPY; ARTICLE; BATTS LUDWIG STAGING CLASSIFICATION SYSTEM; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFECT; FIBROGENESIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; LIVER BIOPSY; LIVER FIBROSIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; STELLATE CELL; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; CHEMOKINE CCL5; GENE EXPRESSION PROFILING; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LEUKOCYTES; LIVER; LIVER CIRRHOSIS; MICROARRAY ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3;

EID: 84855846576     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01503.x     Document Type: Article

References (41)

1. Afdhal NH,. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl 2): 3-8. (Pubitemid 39180700)
2. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH,. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999; 163 (11): 6236-6243.
3. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterolog 2003; 124 (1): 97-104. (Pubitemid 36055343)
4. Reiss G, Keeffe EB,. Role of liver biopsy in the management of chronic liver disease: selective rather than routine. Rev Gastroenterol Disord 2005 Fall; 5 (4): 195-205. (Pubitemid 43009614)
5. Nischalke HD, Nattermann J, Fischer HP, Sauerbruch T, Spengler U, Dumoulin FL,. Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C. Mediators Inflamm 2004; 6: 357-359. (Pubitemid 40018370)
6. Schwabe RF, Bataller R, Brenner DA,. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 2003; 285 (5): G949-G958. (Pubitemid 37310074)
7. Bataller R, Brenner DA,. Liver fibrosis. J Clin Invest 2005; 115 (2): 209-218. (Pubitemid 40385459)
8. Wang B, Trippler M, Pei R, et al. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis c virus replication. J Hepatol 2009; 51 (6): 1037-1045.
9. Batts KP, Ludwig J,. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19 (12): 1409-1417.
10. Huang da W, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4 (1): 44-57.
11. Schrum S, Probst P, Fleischer B, Zipfel PF,. Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. J Immunol 1996; 157 (8): 3598-3604. (Pubitemid 126449174)
12. Kitamura N, Kitamura F, Kaminuma O, et al. IL-4 gene transcription in human T cells is suppressed by T-bet. Int Arch Allergy Immunol 2007; 143 (Suppl 1): 68-70. (Pubitemid 46854795)
13. Pacheco R, Martinez-Navio JM, Lejeune M, et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci U S A 2005; 102 (27): 9583-9588. (Pubitemid 40981724)
14. Smits HH, de Jong EC, Schuitemaker JH, et al. Intercellular adhesion molecule-1/LFA-1 ligation favors human Th1 development. J Immunol 2002; 168 (4): 1710-1716. (Pubitemid 34135768)
15. Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, Pellegrini S,. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J 2003; 22 (3): 537-547. (Pubitemid 36193598)
16. Liew FY, Xu D, Brint EK, O'Neill LA,. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5 (6): 446-458. (Pubitemid 40835033)
17. Shahrara S, Park CC, Temkin V, Jarvis JW, Volin MV, Pope RM,. RANTES modulates TLR4-induced cytokine secretion in human peripheral blood monocytes. J Immunol 2006; 177 (8): 5077-5087. (Pubitemid 44527578)
18. Mauro C, Pacifico F, Lavorgna A, et al. ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J Biol Chem 2006; 281 (27): 18482-18488. (Pubitemid 44035507)
19. Friedman SL,. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88 (1): 125-172.
20. Yang KL, Hung KC, Chang WT, Li EI,. Establishment of an early liver fibrosis model by the hydrodynamics-based transfer of TGF-beta1 gene. Comp Hepatol 2007; 6: 9.
21. Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K,. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007; 120 (3): 280e9-280e14.
22. Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003; 38 (6): 1468-1476. (Pubitemid 37466973)
23. Navratilova Z,. Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150 (2): 191-204.
24. Grayson MH, Holtzman MJ,. Chemokine complexity: the case for CCL5. Am J Respir Cell Mol Biol 2006; 35 (2): 143-146. (Pubitemid 44175312)
25. Pelchen-Matthews A, Signoret N, Klasse PJ, Fraile-Ramos A, Marsh M,. Chemokine receptor trafficking and viral replication. Immunol Rev 1999; 168: 33-49. (Pubitemid 29276671)
26. Lichterfeld M, Leifeld L, Nischalke HD, et al. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. J Infect Dis 2002; 185 (12): 1803-1807. (Pubitemid 34615477)
27. Larrubia JR, Benito-Martinez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T,. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008; 14 (47): 7149-7159.
28. Losana G, Bovolenta C, Rigamonti L, et al. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes. J Leukoc Biol 2002; 72 (4): 735-742. (Pubitemid 36277845)
29. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191 (9): 1499-1512. (Pubitemid 30257347)
30. Wasmuth HE, Werth A, Mueller T, et al. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology 2004; 40 (2): 327-334. (Pubitemid 39062850)
31. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965. (Pubitemid 32913521)
32. Kim JJ, Yang JS, Dentchev T, Dang K, Weiner DB,. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J Interferon Cytokine Res 2000; 20 (5): 487-498. (Pubitemid 30414231)
33. Rogge L, D'Ambrosio D, Biffi M, et al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol 1998; 161 (12): 6567-6574. (Pubitemid 28562196)
34. Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ,. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol 2001; 2: 174-180.
35. Zimmerer JM, Lesinski GB, Radmacher MD, Ruppert A, Carson WE 3rd,. STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha. Cancer Immunol Immunother 2007; 56 (11): 1845-1852. (Pubitemid 47313088)
36. Yang YF, Tomura M, Iwasaki M, et al. IFN-alpha acts on T-cell receptor-triggered human peripheral leukocytes to up-regulate CCR5 expression on CD4+ and CD8+ T cells. J Clin Immunol 2001; 21 (6): 402-409. (Pubitemid 34017074)
37. Foster GR, Masri SH, David R, et al. IFN-alpha subtypes differentially affect human T cell motility. J Immunol 2004; 173 (3): 1663-1670. (Pubitemid 38971597)
38. Lempicki RA, Masur H, Polis MA, Kottilil S,. Genome-wide single polymorphism analysis identifies a unique CCL-5 haplotype in HIV/HCV co-infected non-responders to pegylated Interferon (peg-IFN) and ribavirin (RBV) therapy [abstract]. Hepatology 2009; 50 (Suppl): 690A.
39. Zeremski M, Petrovic LM, Talal AH,. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007; 14 (10): 675-687. (Pubitemid 47414927)
40. Kisseleva T, Brenner DA,. Is it the end of the line for the EMT? Hepatology 2011; 53 (5): 1433-1435.
41. Dranoff JA, Wells RG,. Portal fibroblasts: underappreciated mediators of biliary fibrosis. Hepatology 2010; 51 (4): 1438-1444.